Anti-infectives

Increasing microbial resistance is creating a demand for new drugs, which is currently not matched by privately-funded research and development, making it all the more important to obtain protection with smart, cost effective IP strategies for novel inventions addressing the innovation void.  

The repurposing of drugs can also be protected by patents, which requires experience and expertise in second-medical use claims to provide the best possible support. 

Universities and research institutions, start-up companies and SMEs all benefit from the wide-ranging, commercially relevant experience of HGF’s anti-infectives IP team, who possess deep knowledge and understanding of the shifting patent laws that affect innovators in areas relating to anti-infective agents.  

HGF’s specialist attorneys combine extensive legal, scientific and transactional expertise with in-house backgrounds to develop multijurisdictional IP protection strategies across antibiotics, antivirals, immunomodulators and vaccines, as well as diagnostic methods and technologies.  

The anti-infectives team specialises in patent and trade mark protection, with targeted and industry-validated advice on drafting and prosecuting, including second medical use type claims and cross jurisdictional drafting of patent applications. Furthermore, the attorneys are highly accomplished across oppositions and appeals in biologics, small molecule drugs and diagnostic devices, freedom-to-operate analysis, in-and-out licensing and supplementary protection certificates (SPCs).

Latest updates

What's Next for CAR Cell Therapy?

The first generation CAR T cell was discovered in 1993 when the variable region of an antibody was fused to the constant regions of a T cell receptor.  Now, 20 …

Read article
Event - 30th January 2024

CAR-TCR Summit, Europe 2024

HGF are proud Event Partners of CAR-TCR Europe, which is due to go ahead from 27th – 29th February at ExCeL, Royal Victoria Dock in London. This is the European hub …

Event details

First CRISPR therapy approved for use in the UK

In an unprecedented move, the MHRA has approved a CRISPR gene editing therapy ‘Casgevy’  for the treatment of sickle cell disease and beta-thalassaemia in patients with recurrent vaso-occlusive crises. The Casgevy …

Read article
Event - 23rd-24th April 2024

Microbiome & Probiotic R&D & Business Collaboration Forum: Europe

The Microbiome & Probiotic R&D & Business Collaboration Forum is set to take place in Rotterdam on the 23rd-24th April 2024. This world-renowned event will see three conferences and eight …

Event details

IAM Patent 1000 2023

IAM Patent 1000 the world’s leading patent professionals 2023 guide has now been published and we are delighted to have 31 attorneys recognised as world-class individuals in the guide. The …

Read article

What is EUDAMED and how will it affect your IP strategy?

The “European database on medical devices”, or “EUDAMED”, is the EU’s IT system created by the new Medical Devices Regulation (MDR) and In Vitro Diagnostics Medical Devices Regulation (IVDR). When …

Read article
Event - 8th-9th February 2023

5th Annual Microbiome & Probiotic Conference 2023

The 5th Annual MarketsandMarkets Next Gen Microbiome and Probiotics Conference will take place in San Diego on the 8th-9th of February. This conference will enable you to learn about microbial …

Event details
Event - 29th November 2022

LSPN Europe 2022

HGF is a silver sponsor of LSPN Europe 2022 on 29th November in London. This event will explore some of the biggest challenges facing the Life Sciences Patent Community right now …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our anti-infectives specialists.